GI Hepatobiliary

Hepatocellular Carcinoma

Localized

No Prior Therapy

Prior Therapy

1st Line

2nd Line

1st Line

2nd Line

IRB #23365
A Phase II Study to Evaluate the Efficacy and Safety of Y-90, Atezolizumab and Cabozantinib Among Patients with unresectable and locally-advanced HCC

IRB# 20929
Phase II study of TSR-022 (COBOLIMAB) in combination with TSR-042 (DOSTARIMAB) for the treatment of advanced hepatocellular carcinoma

IRB# 20357 [NCI CIRB] A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

IRB# 16033
Phase II study of induction systemic mFOLFIROX followed by hepatic arterial infusion of Floxuridine and Dexamethasone given concurrently with systemic mFOLFIROX as a first-line therapy in patients with unresectable liver-dominant intrahepatic cholangiocarcinoma

Cholangiocarcinoma

1st Line

1st or 2nd Line

2nd Line or more

IRB #20744
Pembrolizumab + Lenvatinib + TACE (Transarterial Chemoembolization) vs Placebo + TACE in Intermediate Stage HCC

IRB #20357
[NCI CIRB] A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

IRB# 21797
A Phase 2b, open-label, single-arm study of ZW25 monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers

No Trials Currently Available

No Trials Currently Available

CROSS-DISEASE TRIALS:

IRB# TBD
EAY131 (MATCH)

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result
IRB# 23005
EA2197, Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial

03 JAN 2022

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result